Get the Stockscreener App
37.73
3.08%
-1.20
Pre-market:
39.00
1.27
+3.37%
Tyra Biosciences Inc stock is traded at $37.73, with a volume of 841.70K.
It is down -3.08% in the last 24 hours and up +7.68% over the past month.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
See More
Previous Close:
$38.93
Open:
$38.63
24h Volume:
841.70K
Relative Volume:
0.89
Market Cap:
$2.03B
Revenue:
-
Net Income/Loss:
$-119.95M
P/E Ratio:
-18.75
EPS:
-2.0123
Net Cash Flow:
$-95.28M
1W Performance:
-1.49%
1M Performance:
+7.68%
6M Performance:
+182.20%
1Y Performance:
+411.25%
1-Day Range:
$37.13
$39.30
1-Week Range:
$37.10
$40.65
52-Week Range:
$6.42
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
(619) 728-4760
Address
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
37.73 | 2.03B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-21-25 | Resumed | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | UBS | Buy |
| Oct-18-24 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-15-24 | Initiated | Piper Sandler | Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-23 | Initiated | Wedbush | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Jun-23-22 | Initiated | H.C. Wainwright | Buy |
| Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Oct-11-21 | Initiated | Cowen | Outperform |
| Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - stocktitan.net
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Growth Stocks To Watch Now – April 3rd - Defense World
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - finance.yahoo.com
Promising Growth Stocks To Watch Today – April 2nd - defenseworld.net
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks
Tyra Biosciences (TYRA) VP details multi-year stock option grants - stocktitan.net
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - stocktitan.net
Tyra Biosciences, Inc. Announces Principal Accounting Officer Changes, Effective April 1, 2026 - marketscreener.com
Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Growth Stocks Worth Watching – March 31st - Defense World
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighWhat's Next? - MarketBeat
Tyra Biosciences stock hits all-time high at 39.21 USD - investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% HigherShould You Buy? - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat
Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - Investing.com Australia
Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan
Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN
Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm
Best Growth Stocks To Follow Today – March 20th - Defense World
Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World
Technical Reactions to TYRA Trends in Macro Strategies - news.stocktradersdaily.com
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm
Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com
Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Tyra Biosciences Inc Stock (TYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tyra Biosciences Inc Stock (TYRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Mar 25 '26 |
Sale |
36.97 |
14,295 |
528,506 |
28,231 |
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):